{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~34 mi. (Bristol, United Kingdom, +226 more cities)
facility
University Hospitals Bristol NHS Foundation Trust ( Site 0530)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~34 mi. (Bristol, United Kingdom, +207 more cities)
facility
University Hospitals Bristol NHS Foundation Trust ( Site 1503)
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
city
~34 mi. (Bristol, United Kingdom, +201 more cities)
facility
University Hospitals Bristol NHS Foundation Trust /ID# 222510
drug
azacitidine, +1 more drug
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
city
~34 mi. (Bristol, United Kingdom, +145 more cities)
facility
University Hospitals Bristol NHS Foundation Trust ( Site 1802)
drug
pembrolizumab, +1 more drug
drug type
immunotherapy, +2 more types
A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
city
~34 mi. (Bristol, United Kingdom, +197 more cities)
facility
University Hospitals Bristol /ID# 215911
biomarker
BCR-ABL1 Fusion, +47 more biomarkers
drug
azacitidine, +1 more drug
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition and/or Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Chemotherapy Resistant Residual Triple Negative Breast Cancer
city
~34 mi. (Bristol, United Kingdom, +8 more cities)
facility
Bristol Haematology and Oncology Centre
biomarker
ER Negative, +2 more biomarkers
drug
ceralasertib, +2 more drugs
drug type
immunotherapy, +1 more type
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
city
~37 mi. (Cheltenham, United Kingdom, +42 more cities)
facility
Gloucestershire Hospitals NHS Foundation Trust /ID# 241189
condition
Chronic Myelomonocytic Leukemia, +3 more conditions
drug
celecoxib, +2 more drugs
drug type
Other, +1 more type